Deep tech requires deep analysis.

Members get access to our research, price targets, and a real-time margin of safety for emerging synthetic biology and biotech stocks.

Can biotech stocks beat the S&P 500?

We don't tell you every stock is a buy. But our research occasionally uncovers hidden gems. From our inception through February 12, 2024, stocks that earned our coveted Asymmetric Opportunity label delivered an average return of 49.4% and outperformed the S&P 500 by 29.8%.

Not an investor? The rest of our platform is free.

Subscriptions to investment research ensure our platform has long-term sustainability. As a public benefit company, we publish free analysis of the technologies, companies, and industries powering the global bioeconomy.

Open-source databases (beta).

The Solt DB Biotech Company Database is a historical record of companies across all biotech sectors, not just biopharma. For investment research, biotech job searches, and tracking trends in the bioeconomy.